Quarterly report pursuant to Section 13 or 15(d)

DEVELOPMENT AWARDS (Details Narrative)

DEVELOPMENT AWARDS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended			36 Months Ended
DEVELOPMENT AWARDS (Details Narrative) - USD ($)	May 31, 2019	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Jan. 26, 2018
Entity Listings [Line Items]
Revenue			$ 136,558	$ 286,346			$ 784,382	$ 2,048,405
CFF Warrant [Member]
Entity Listings [Line Items]
Warrant exercisable price per share			$ 13.20				$ 13.20
Cystic Fibrosis Foundation [Member]
Entity Listings [Line Items]
Payments for royalty	$ 2,700,000
Collaboration and License Agreement [Member]
Entity Listings [Line Items]
Revenue from related parties, recorded as deferred revenue					$ 27,000,000
Collaboration and License Agreement [Member] \| Kaken Pharmaceutical Co., Ltd. [Member]
Entity Listings [Line Items]
Upfront payment, received from related party						$ 27,000,000
Consideration receivable on milestone payments		$ 173,000,000
Royalty term description		The “Royalty Term” means the period beginning on the date of the first commercial sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party’s insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days’ notice.
Contract with customer, liability, current		$ 27,000,000				27,000,000
Revenue from related parties, recorded as deferred revenue		27,000,000
Royalty payable		$ 27,000,000				$ 27,000,000
Cystic Fibrosis Program Related Investment Agreement [Member] \| Phase 2b Clinical Trial [Member]
Entity Listings [Line Items]
Royalty payable	2,700,000
Payments for royalty	$ 27,000,000
Proceeds from investments on achieving milestones									$ 22,500,000
Loans Payable			$ 2,500,000				$ 2,500,000
Cystic Fibrosis Program Related Investment Agreement [Member] \| Maximum [Member]
Entity Listings [Line Items]
Gain Contingency, Unrecorded Amount														$ 25,000,000
Investment Agreement [Member] \| 2018 CFF Award [Member]
Entity Listings [Line Items]
Revenue			$ 136,558	$ 286,346			$ 784,382	$ 2,048,405
Investment Agreement [Member] \| CFF Warrant [Member]
Entity Listings [Line Items]
Warrant to purchase of common stock			1,000,000				1,000,000
Warrants expiration term										Jan. 26, 2025			Jan. 26, 2025
Investment Agreement [Member] \| CFF Warrant [Member] \| Immediately Exercisable Warrants [Member]
Entity Listings [Line Items]
Warrant to purchase of common stock			500,000				500,000
Investment Agreement [Member] \| CFF Warrant [Member] \| Warrants Exercisable On Completion Of Final Milestone [Member]
Entity Listings [Line Items]
Warrant to purchase of common stock			500,000				500,000
Investment Agreements [Member]
Entity Listings [Line Items]
Revenue							$ 0			$ 5,000,000	$ 5,000,000	$ 12,500,000	$ 22,500,000
Contract asset							2,403,000			$ 1,618,000
Investment Agreements [Member] \| Cystic Fibrosis Foundation Warrants [Member]
Entity Listings [Line Items]
Revenue							25,000,000
Additional paid in capital, fair value of warrant issued							6,215,225
Revenue to be recognized			$ 18,784,775				$ 18,784,775